dapsone (aczone) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dapsone was synthesized in 1908 by Fromm and Wittmann. The drug was approved by FDA for the treatment of such conditions as acne vulgaris, leprosy and dermatitis herpetiformis, also the drug is used off-label for many skin diseases. Although the exact mechanism of dapsone action is unknown, it is speculated that it acts as both anti-inflammatory and antimicrobial agent. It was demonstrated that dapsone suppresses ROS generation, inhibits neutrophil myeloperoxidase and eosinophil peroxidase and also inhibits bacterial dihydropteroate synthase.   NCATS

Chemistry

  • SMILES: NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(N)C=C2
  • InChIKey: MQJKPEGWNLWLTK-UHFFFAOYSA-N
  • Mol. Mass: 248.301
  • ALogP: 1.68
  • ChEMBL Molecule:
    dapsone  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.4797 - $11.2843

Australia

$1.8175 - $2.2303
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,1'-sulfonylbis(4-aminobenzene) | 1,1'-sulfonylbis[4-aminobenzene] | 4-(4-amino-benzenesulfonyl)-phenylamine | 4-(4-aminophenylsulfonyl)aniline | 4-(4-aminophenylsulfonyl)benzenamine | 4,4'-dapsone | 4,4'-diaminodiphenylsulfone | 4,4'-diaminodiphenyl sulfone | 4,4'-diaminodiphenyl sulphone | 4,4'-sulfonylbisaniline | 4,4'-sulfonylbisbenzenamine | 4,4'-sulfonylbisbenzeneamine | 4,4'-sulfonyldianilin | 4,4'-sulfonyldianiline | 4-aminophenyl sulfone | aczone | bis(4-aminophenyl)sulfone | bis(p-aminophenyl) sulfone | dadps | dapson | dapsona | dapsone | dapsone mixture with pyrimethamine | dapsonum | dds | diaminodiphenylsulfone | diaphenylsulfon | diaphenylsulfone | p-aminophenyl sulfone | p,p'-diaminodiphenyl sulfone | p,p-sulphonylbisbenzamine | p,p-sulphonylbisbenzenamine | sulphadione

Organizations (112)

Research & Development (101)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (45)

Approved Indications (4)


 

Acne Vulgaris

Dermatitis Herpetiformis

Leprosy (approved 1979)

Purpura, Thrombocytopenic, Idiopathic

Experimental Indications - Clinical Trial Phases 1-4 (43)


 

Acne Vulgaris ()

Acute Generalized Exanthematous Pustulosis (Phase 4)

Bacterial Infections (Phase 1)

Brain Ischemia (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

COVID-19 (Phase 3)

Dapsone (Phase 3)

Exanthema (Phase 2)

Fever (Phase 3)

Healthy Volunteers (Phase 1)

HIV Infections (Phase 3)

Hypoxia (Early Phase 1)

IgA Vasculitis (Phase 2)

Leprosy (Phase 4)

Linear IgA Bullous Dermatosis (Phase 1)

Lung Diseases (Phase 2)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Malaria, Vivax (Phase 3)

Methemoglobinemia (Phase 1)

Mycoses (Phase 1)

Neoplasms (Phase 2)

Obesity (Phase 4)

Pemphigoid, Benign Mucous Membrane (Phase 2/Phase 3)

Pemphigus (Phase 2)

Pneumonia, Pneumocystis (Phase 4)

Polyarteritis Nodosa (Phase 2)

Psoriasis (Phase 4)

Pulmonary Fibrosis (Phase 2)

Purpura (Phase 2)

Rosacea (Phase 2)

Sarcoidosis (Phase 2)

SARS-CoV-2 (Early Phase 1)

Severe Acute Respiratory Syndrome (Phase 1)

Skin Diseases, Vesiculobullous (Phase 4)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Stroke (Phase 2/Phase 3)

Subarachnoid Hemorrhage (Phase 3)

Thrombocytopenia (Phase 3)

Tuberculosis (Phase 4)

Urticaria (Phase 4)

Vasculitis, Leukocytoclastic, Cutaneous (Phase 4)

Vasospasm, Intracranial (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 77
  • # of Trial Organizations: 101

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue